📌 Key Takeaways
- Topic: What Is Amorphous Silica? Types, Safety Profile and Industrial Uses
- Keywords: E551
- Published: 2026-11-20 02:07:52
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Imerys Silica: Product Range, Minerals and Applications
- Silica Supplier Brazil: Market Overview, Producers and Import Considerations
- Mesoporous carriers also offer an attractive alternative in the oral therapy of macromolecules rather than the more complicated parenteral administration. Peptides and proteins may denature in the greatly acidic environment of the stomach, lose their structure and function [ 1, 13 ], while the proteases in the digestive system break down the protein chains, making the molecule useless and the therapy ineffective [ 1, 13, 91 ]. Additionally, poor permeation through the epithelium is another hindering component during the oral administration of macromolecules [ 1, 13 ]. The macromolecule locked inside the pores stays protected against enzymatic or chemical degradation, and its permeation through the epithelium can also be improved [ 1, 13, 91 ]. It is also true that smaller pores deliver better protection for macromolecules against degradation [ 1 ]. Mesoporous silica nanocarriers have extra intriguing advantages because of their special properties that make them outstanding over other carriers and therefore provide a popular alternative in formulating macromolecules [ 1, 13 ].
- 2500 Mesh Silica: Particle Size, Specifications and Common Applications
- Nevertheless, mesoporous carriers are frequently associated with poor tabletability because of bad powder flow behavior; thus, direct tableting can only be attained by adding diverse excipients in large quantities [ 95 ]. Such useful excipients include microcrystalline cellulose (filler), lactose monohydrate (filler), PVP (binder), sodium carboxymethylcellulose (disintegrant), croscarmellose sodium (super disintegrant), colloidal silica (anti-adhesion material), magnesium stearate (lubricant), and talc (lubricant) [ 39, 95, 96, 97 ]. However, the drug content in the dosage unit decreases with high amounts of excipients added, so larger tablets must be designed to attain the proper dose [ 95 ]. Another issue is that the greater compression force used during tableting may deform and damage the pore structure of the carrier, which might decrease the expected drug release rate [ 36, 97, 98 ]. When higher compression forces are applied, the pore diameter decreases, which affects both total pore volume and particular surface region, reducing the drug release rate from the carrier [ 97, 98 ]. The use of microcrystalline cellulose may be a solution to this problem, as it deforms plastically under pressure while distributing the energy accumulated in the tablet during compression. Furthermore, croscarmellose sodium may improve the drug release rate [ 97, 98 ]. Granulation of mesoporous material is a proper choice to solve issues related to poor powder rheology.
- Silica Tapped Density: Definition, Measurement and Typical Values
- Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
- Angular Silica Powder: Properties, Uses and When to Choose It Over Spherical Silica
Fumed Silica Market 2026: Size, Growth, Key Players and Forecast
What is silica (SiO₂)?
kaolin
What is the difference between fumed silica and precipitated silica?
silica supply chain
What drives silica raw material prices?
transparent silica filler MSNs are SiO 2 nanoparticles [ 2 ] with a pore diameter between 2 and 50 nm [ 3, 4 ] and with a total diameter of a maximum of 1 µm. Their use in drug delivery dates to the early 1990s when they were synthesized for various scientific applications [ 5 ]. The material known as mesoporous silica was discovered by Mobil Oil Corporation in 1992 [ 6 ]. Their first drug delivery application was demonstrated in 2001 when MCM-41 silica was used to release ibuprofen [ 7 ]. Since then, MSNs have become an increasingly popular drug delivery system due to their advantageous properties and have been typically recognized as secure (GRAS) by the FDA. Tiny SNPs have been approved for human clinical imaging studies, setting the stage for their use in clinical applications of drug delivery. The number of related research activities is continuously increasing each year, expanding their role in cancer treatment, gene delivery, and oral illness therapy [ 5 ]. Their pore size is located between microporous and macroporous systems. They can be used in diverse shapes (sphere, cube, ellipsoid, rod) and sizes, with different pore sizes and pore structures [ 2, 3, 4, 8, 9, 10 ]. They have a high degree of stability [ 8 ] and a rigid framework, which results in resistance to temperature, pH, enzymatic degradation, and mechanical force [ 4 ]. Thanks to the large number of pores, they have a massive particular surface region (approx. 700-1300 m 2 /g) and pore volume (approx. 0.5-1.5 cm 3 /g), which enables effective adsorption of diverse molecules [ 2, 3, 4, 8, 9, 10 ]. By changing the pore size distribution, the range of adsorbable molecules can be controlled [ 3 ], which also lets separation based on size exclusion, which means selective adsorption of molecules of certain sizes. Depending on the size of the pores, tiny molecules together with high molecular weight proteins can be transported into the pores [ 8 ]. In addition, chemical separation is also possible if the surface of the pores is coated with specific functional groups [ 4 ], which enables the separation of the APIs according to their structure [ 4 ]. Such modifications may include the setting of hydrophilicity/hydrophobicity of the surface, depending on whether the adsorption of hydrophobic or hydrophilic molecules is targeted [ 4 ]. By inserting different functional groups, the surface charge can also be controlled so that certain molecules will bind more efficiently. MSNs have a negative surface charge in biological environments, which promotes the electrostatic adsorption of positively charged APIs in the pores [ 10 ]. Moreover, the biological markers attached to the surface of the nanoparticles enable the drug-carrying system to deliver the API in a tissue-specific manner [ 2, 4, 8, 9, 10 ]. A substantial problem is the premature release of the API from the pores during transport [ 4, 8 ], which can be solved by utilizing gatekeepers that respond to special stimuli and keep the pores closed until the stimulus [ 2, 4, 8 ]. In this way, controlled drug delivery and stimuli-responsive release can be achieved [ 2, 4, 9 ]. The drug release could be triggered by temperature, pH, redox potential, light, enzymes, magnetic field, or different ligands [ 4, 8, 11 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.